Rating date
Jul 1, 2026
40 days ago
Medtronic (MDT) Stock Analysis
BUYMDT Equity Research — BUY — July 2026
Desk view
BUY
5D move
—
Awaiting market data
Peer rank
38p
Research history
2026-08-072026-07-202026-07-012026-06-252026-06-182026-06-162026-06-082026-06-02+1 moreInvestment card · MDT
Here is the equity analysis note for MDT (Medtronic plc).
Desk rating
BUY
Tactical BUY · 12M BUY
Horizon
Long-term
Confidence
High
Invalidation
Thesis weakens if catalysts slip or risk markers breach stated levels.
Bias
BUY
Catalysts
- Structural downtrend intact — MDT remains below both the 50- and 200-day SMAs, and both averages are declining. The path of least resistance on a multi-month horizon is still downward until proven otherwise.
- Near-term momentum has improved — The RSI has recovered from oversold to neutral, and the MACD is positive for the first time since early 2026. This suggests selling exhaustion, at least temporarily.
- Critical test at the 50-day SMA (~$78.40) — The stock ended June essentially right at this level. A decisive break above with follow-through would target the $80–$82 zone (Bollinger upper band). A rejection would risk retesting the June lows near $73.
Risks
- Event-driven repricing risk if expectations diverge from incoming evidence.
Market chart
Price context alongside the research narrative.
MDT Research Note
Full desk note for Jul 1, 2026. Use tabs for catalysts, valuation and risks, or open the full note.
WebserviceX · Agentic Research Desk
MDT Equity Research Note
MDT Stock Rating Summary
MDT bias
BUY
Horizon
Long-term
MDT key risk
Event-driven repricing risk if expectations diverge from incoming evidence.
MDT catalyst watch
Structural downtrend intact — MDT remains below both the 50- and 200-day SMAs, and both averages are declining. The path of least resistance on a multi-month horizon is still downward until proven otherwise.
Invalidation
Thesis weakens if catalysts slip or risk markers breach stated levels.
Confidence
High
How the call aged · 5D
—Awaiting market dataPeer 38pExpandCollapse
How the call aged · 5D
—Awaiting market dataPeer 38p
Grading rule: BUY/OVERWEIGHT scores Correct when forward return > 0; UNDERWEIGHT/SELL when < 0; HOLD is Neutral. Window uses 5 US trading sessions after the rating entry close vs benchmark SPY. Scorecard computed 2026-07-02T20:45:25.437076+00:00.
5D move
—
2026-07-01 → awaiting
Outcome
Awaiting market data
5D trend
-0.27%
Vol (20D ann.)
+35.66%
vs SPY: -1.98%
Close 79.2 → — (USD, vendor closes)
Publish QC
passedExpandCollapse
Publish QC
passed
Pipeline fingerprint 2f45a102687f75c0
Trace 00a3a007…
No QC issues recorded.